←
ArteraAI703 posts
ArteraAI avatar✓

ArteraAI ✓

@arteraAI

A leading precision medicine company, ArteraAI develops AI-enabled tests to help personalize therapy for cancer patients.

◷ Joined February 2022▧ 541 Photos and videos
ArteraAI avatar
ArteraAI@arteraAI·Jan 9

Dr. Daniel Spratt on Artera’s Post‑RP test: “[It] uses clinical and pathologic features + digital pathology, running AI to help ID patients at low vs high risk of recurrence and metastasis.” Thanks @UroTimes + Hannah Clarke for the feature. heyor.ca/mI71pa #ArteraAI

ArteraAI avatar
ArteraAI@arteraAI·16h

We're heading to #SUO2026! The Artera team looks forward to connecting with the urologic oncology community and discussing how AI-powered biomarkers can help inform personalized prostate cancer care. #ArteraOnTheGo

Post attachment
ArteraAI avatar
ArteraAI@arteraAI·Nov 16

Big news! The ArteraAI Prostate Test (Post-RP) is now included in the @NCCN Guidelines for Prostate Cancer as a risk stratification tool following biochemical recurrence after surgery. Another milestone in personalized care. buff.ly/BW4i5xo

Post attachment
ArteraAI avatar
ArteraAI@arteraAI·Nov 11

The Artera team is heading to the Puerto Rico Urological Association Annual Meeting to connect with colleagues and discuss advances in personalized prostate cancer care. See you there! #ArteraOnTheGo

Post attachment
ArteraAI avatar
ArteraAI@arteraAI·Nov 9

That's a wrap on #LUGPA2026! Thank you to everyone who connected with the Artera team in Chicago. We enjoyed the conversations and the opportunity to exchange ideas with the urology community.

Post attachmentPost attachmentPost attachment
ArteraAI avatar
ArteraAI@arteraAI·Nov 6

The future of AI in cancer care depends on more than better algorithms. In @TheAIJournal1, Artera explores why rigorous validation, real-world reliability, and strong clinical evidence are essential to responsible AI adoption. Read the full article: buff.ly/RDYa0b7

Post attachmentPost attachment
ArteraAI avatar
ArteraAI@arteraAI·Nov 4

What could precision medicine look like in five years? On PathPulse, Artera's Laura Chang shares her vision for expanding AI-powered biomarkers across diseases and making them more accessible worldwide. Watch the interview: buff.ly/Gnc0ySa @LumeaDigital

Post attachment
ArteraAI avatar
ArteraAI@arteraAI·Oct 26

We're heading to #LUGPA26! The Artera team looks forward to connecting with the urology community and discussing how AI-powered biomarkers can help inform personalized prostate cancer care. See you there! @UrologyUS

Post attachmentPost attachment
ArteraAI avatar
ArteraAI@arteraAI·Oct 24

That's a wrap on #PathVisions26! Thank you to everyone who connected with the Artera team. We enjoyed exchanging ideas and discussing the future of digital pathology and AI-powered diagnostics.

Post attachmentPost attachmentPost attachmentPost attachment
ArteraAI avatar
ArteraAI@arteraAI·Oct 21

AI biomarkers should work across the diverse populations they're intended to serve. New data presented at #ASTRO2026 found similar performance of the ArteraAI prostate biomarker across racial and age subgroups studied, with no evidence of bias. Read more: buff.ly/KbGFjsM

Post attachment